Similarly, the binding assay to hERG indicated that these molecules may share a potential liability for cardiovascular side effects with the quinoline antimalarials, including chloroquine and piperaquine, currently recommended by WHO for malaria therapy [33]. This evidence concerns the gene KCNH2 and malaria.